Pivekimab Sunirine Yields Enduring Responses in Frontline BPDCN Trial
A critical clinical trial of Pivekimab Sunirine demonstrates promising responses in frontline BPDCN treatment.
FDA Issues Partial Clinical Hold on Lorigerlimab Trial in Gynecologic Cancers
The FDA has imposed a partial clinical hold on the Lorigerlimab trial for gynecologic cancers due to serious safety events.
Refining Management of Immune-Checkpoint Inhibitor Toxicities in Melanoma
Effort is underway to refine the management of immune-checkpoint inhibitor toxicities in melanoma treatment.
FDA Grants Fast Track Designation to SRN-101 for Recurrent High-Grade Glioma
The FDA has awarded a Fast Track Designation to SRN-101 for treating recurrent high-grade glioma.
Novel Small Molecule Shows Early Activity in Pretreated Multiple Myeloma
An innovative small molecule exhibits early beneficial activity in pretreated multiple myeloma.
Comparing Quality of Life Outcomes with Protons vs Photons in OPSCC
Insights into a comparative analysis of life quality outcomes with Protons versus Photons in OPSCC treatments.
